Vimarsana
Biggest News Aggregation in the World

Page 26 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference - Vimarsana News

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology companytoday announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conferenceon Monday, January

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab - Vimarsana News

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company

BeiGene's BRUKINSA (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH - Vimarsana News

BeiGene's BRUKINSA (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual

BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors - Vimarsana News

BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors

09.12.2022 - BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) ... Seite 1

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022 - Vimarsana News

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022

22.11.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation ... Seite 1